| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Tuesday, March 31, 2020 1:45:20 AM
marjac....
Amarin's lawyers should have jumped on the fact that "Mori" was not only not published in "peer reviewed" medical journal It was not published in a medical journal...But rather it was published in a Nutritional Journal. And this would not be considered acceptable by any medical society..Also the study was very slipshod...With 59 male slightly obese males with mildly elevated trigs...The ranges were not given..we know 56 individuals finished the trial, but we know nothing about their ages..whether some were diabetic...whether they had other comorbidities..
In short "Mori" lacked the structure to be considered a valid clinical trial because it lacked information on who were being treated. The FDA would not consider this a valid clinical trial...So Du who is not a physician nor is there any evidence that she has any medical background decides she knows more about this very complicated issue than the experts and feels free to throw out millions of dollars of research and the FDA process and throw them out the window because she determines the results were obvious...The FDA did not think EPA's effects were obvious...they dam sure made the company finish the trial..
This country which my father and my mother died in the service of the army and I went to Vietnam for is going to hell because we have these liberals and leftists...And a bunch of phonies crying social injustice and slinging names around...Well this is the payoff.. Our free loading leaders don't give a dam about how hard we work and how much money we spend on improving medicine...And let these thieving maggots steal away all our hard earned accomplishments..
Nobody has mentioned Trump..He should hear about this...
":>) JL
Amarin's lawyers should have jumped on the fact that "Mori" was not only not published in "peer reviewed" medical journal It was not published in a medical journal...But rather it was published in a Nutritional Journal. And this would not be considered acceptable by any medical society..Also the study was very slipshod...With 59 male slightly obese males with mildly elevated trigs...The ranges were not given..we know 56 individuals finished the trial, but we know nothing about their ages..whether some were diabetic...whether they had other comorbidities..
In short "Mori" lacked the structure to be considered a valid clinical trial because it lacked information on who were being treated. The FDA would not consider this a valid clinical trial...So Du who is not a physician nor is there any evidence that she has any medical background decides she knows more about this very complicated issue than the experts and feels free to throw out millions of dollars of research and the FDA process and throw them out the window because she determines the results were obvious...The FDA did not think EPA's effects were obvious...they dam sure made the company finish the trial..
This country which my father and my mother died in the service of the army and I went to Vietnam for is going to hell because we have these liberals and leftists...And a bunch of phonies crying social injustice and slinging names around...Well this is the payoff.. Our free loading leaders don't give a dam about how hard we work and how much money we spend on improving medicine...And let these thieving maggots steal away all our hard earned accomplishments..
Nobody has mentioned Trump..He should hear about this...
":>) JL
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
